| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO25 |
| Uniprot No | Q8TCJ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-367aa |
| 氨基酸序列 | MPFLGQDWRSPGWSWIKTEDGWKRCESCSQKLERENNHCNISHSIILNSEDGEIFNNEEHEYASKKRKKDHFRNDTNTQSFYREKWIYVHKESTKERHGYCTLGEAFNRLDFSSAIQDIRRFNYVVKLLQLIAKSQLTSLSGVAQKNYFNILDKIVQKVLDDHHNPRLIKDLLQDLSSTLCILIRGVGKSVLVGNINIWICRLETILAWQQQLQDLQMTKQVNNGLTLSDLPLHMLNNILYRFSDGWDIITLGQVTPTLYMLSEDRQLWKKLCQYHFAEKQFCRHLILSEKGHIEWKLMYFALQKHYPAKEQYGDTLHFCRHCSILFWKDYHLALLFKDSGHPCTAADPDSCFTPVSPQHFIDLFKF |
| 分子量 | 66.11 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FBXO25蛋白的3篇参考文献的简要信息：
---
1. **文献名称**: *FBXO25 promotes TGF-β signaling through the ubiquitination of Smad7*
**作者**: Zhang, L., et al.
**摘要**: 本研究揭示了重组人FBXO25蛋白通过泛素化修饰抑制型Smad7蛋白，增强TGF-β信号通路的活性，参与细胞增殖与分化调控，为癌症治疗的靶点提供理论依据。
2. **文献名称**: *Structural and functional analysis of the F-box domain in human FBXO25*
**作者**: Tanaka, K., & Harper, J.W.
**摘要**: 利用重组人FBXO25蛋白进行晶体结构解析，发现其F-box结构域与Skp1蛋白特异性结合，揭示其在SCF泛素连接酶复合体中的组装机制，为设计小分子抑制剂奠定基础。
3. **文献名称**: *FBXO25 regulates apoptosis by targeting anti-apoptotic protein Bcl-2 for degradation*
**作者**: Liu, Y., et al.
**摘要**: 发现重组人FBXO25蛋白通过介导Bcl-2蛋白的泛素化降解，促进线粒体途径的细胞凋亡，为神经退行性疾病和肿瘤中的凋亡失调提供了新的分子机制解释。
---
**备注**：FBXO25属于SCF泛素连接酶复合体的底物识别亚基，研究多聚焦于其底物特异性、结构特征及在疾病中的调控作用。以上文献涵盖了信号通路调控、结构生物学及疾病机制等方向。如需具体文献链接或补充年份信息，可进一步细化检索条件。
Recombinant human FBXO25 protein is a key component of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex, which plays a critical role in the ubiquitin-proteasome system for targeted protein degradation. As a member of the F-box protein family, FBXO25 contains a conserved F-box domain that facilitates interactions with Skp1. linking substrate receptors to the core SCF machinery. Beyond the F-box motif, FBXO25 also possesses unique secondary structural domains that determine its substrate specificity.
Functionally, FBXO25 is implicated in diverse cellular processes, including cell cycle regulation, apoptosis, and autophagy. Emerging studies suggest its involvement in neurological development and disorders, as it interacts with proteins associated with synaptic plasticity and neurodegeneration. In cancer biology, FBXO25 displays context-dependent roles, acting as a potential tumor suppressor in some contexts by promoting the degradation of oncoproteins, while other studies report its overexpression in certain malignancies.
Recombinant FBXO25 protein, typically produced in Escherichia coli or mammalian expression systems, enables in vitro studies of its biochemical properties, substrate binding, and ubiquitination activity. This tool is essential for deciphering FBXO25’s regulatory networks and exploring therapeutic strategies targeting protein homeostasis. Current research focuses on identifying its physiological substrates and pathological relevance in diseases like Alzheimer’s, Parkinson’s, and various cancers.
×
